MLMi-Young Lee

Mi-Young Lee

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Mi-Young Lee has a total of 11 co-authors. Here are the top co-authors by number of shared publications:

  • Harold I. Saavedra

    Department of Radiation Oncology, Winship Cancer Institute, Emory University School of Medicine, C3084, 1365C Clifton Road NE, Atlanta, GA 30322, USA

    2 shared publications
  • Jamie L King

    Department of Radiation Oncology, Winship Cancer Institute, Emory University School of Medicine, C3084, 1365C Clifton Road NE, Atlanta, GA 30322, USA

    1 shared publication
  • Katie R. Hagen

    Integrated Research Facility, Division of Clinical Research, National Institute of Allergy and Infectious Diseases, National Institutes of Health, 8200 Research Plaza, Fort Detrick, Frederick, MD 21702, USA

    1 shared publication
  • Mary Kathryn Harrison Pitner

    Department of Radiation Oncology, Emory University School of Medicine, Atlanta, USA

    1 shared publication
  • Mihaela Marina

    Department of Radiation Oncology, Winship Cancer Institute, Emory University School of Medicine, C3084, 1365C Clifton Road NE, Atlanta, GA 30322, USA

    1 shared publication
  • Ruth M O’rEgan

    Department of Medical Oncology, Emory University School of Medicine, Atlanta, USA

    1 shared publication

Latest Publications

  • Open Access

    Differential expression of centrosome regulators in Her2+ breast cancer cells versus non-tumorigenic MCF10A cells

    by Mi-Young Lee, Mihaela Marina, Jamie L King, Harold I Saavedra

    Centrosome amplification (CA) amongst particular breast cancer subtypes (Her2+ subtype) is associated with genomic instability and aggressive tumor phenotypes. However, changes in signaling pathways associated with centrosome biology have not been fully explored in subtype specific models. Novel centrosome regulatory genes that are selectively altered in Her2+ breast cancer cells are of interest in discerning why CA is more prevalent in this subtype. To determine centrosome/cell cycle genes that are altered in Her2+ cells that display CA (HCC1954) versus non-tumorigenic cells (MCF10A), we carried out a gene microarray. Expression differences were validated by real-time PCR and Western blotting. After the microarray validation, we pursued a panel of upregulated and downregulated genes based on novelty/relevance to centrosome duplication. Functional experiments measuring CA and BrdU incorporation were completed after genetic manipulation of targets (TTK, SGOL1, MDM2 and SFRP1). Amongst genes that were downregulated in HCC1954 cells, knockdown of MDM2 and SFRP1 in MCF10A cells did not consistently induce CA or impaired BrdU incorporation. Conversely, amongst upregulated genes in HCC1954 cells, knockdown of SGOL1 and TTK decreased CA in breast cancer cells, while BrdU incorporation was only altered by SGOL1 knockdown. We also explored the Kaplan Meier Plot resource and noted that MDM2 and SFRP1 are positively associated with relapse free survival in all breast cancer subtypes, while TTK is negatively correlated with overall survival of Luminal A patients. Based on this functional screen, we conclude that SGOL1 and TTK are important modulators of centrosome function in a breast cancer specific model.


  • Open Access

    Silencing CDK4 radiosensitizes breast cancer cells by promoting apoptosis

    by Katie R Hagen, Xiangbin Zeng, Mi-Young Lee, Shannon Tucker Kahn, Mary Kathryn Harrison Pitner, Sandra S Zaky, Yuan Liu, Ruth M O’rEgan, Xingming Deng, Harold I Saavedra

    Background: The discovery of molecular markers associated with various breast cancer subtypes has greatly improved the treatment and outcome of breast cancer patients. Unfortunately, breast cancer cells acquire resistance to various therapies. Mounting evidence suggests that resistance is rooted in the deregulation of the G1 phase regulatory machinery.Methods: To address whether deregulation of the G1 phase regulatory machinery contributes to radiotherapy resistance, the MCF10A immortalized human mammary epithelial cell line, ER-PR-Her2+ and ER-PR-Her2- breast cancer cell lines were irradiated. Colony formation assays measured radioresistance, while immunocytochemistry, Western blots, and flow cytometry measured the cell cycle, DNA replication, mitosis, apoptosis, and DNA breaks.Results: Molecular markers common to all cell lines were overexpressed, including cyclin A1 and cyclin D1, which impinge on CDK2 and CDK4 activities, respectively. We addressed their potential role in radioresistance by generating cell lines stably expressing small hairpin RNAs (shRNA) against CDK2 and CDK4. None of the cell lines knocked down for CDK2 displayed radiosensitization. In contrast, all cell lines knocked down for CDK4 were significantly radiosensitized, and a CDK4/CDK6 inhibitor sensitized MDA-MB-468 to radiation induced apoptosis. Our data showed that silencing CDK4 significantly increases radiation induced cell apoptosis in cell lines without significantly altering cell cycle progression, or DNA repair after irradiation. Our results indicate lower levels of phospho-Bad at ser136 upon CDK4 silencing and ionizing radiation, which has been shown to signal apoptosis.Conclusion: Based on our data we conclude that knockdown of CDK4 activity sensitizes breast cancer cells to radiation by activating apoptosis pathways.